Donidalorsen delivered significant and sustained reductions in HAE attacks, with high levels of disease control and improvement in quality of life measures with monthly or every two-month dosing;.
Otsuka to leverage strong commercial infrastructure and rare disease experience to reach European HAE patientsIonis plans to independently bring donidalorsen to U.S. patients if approvedDonidalorsen.
Ionis presents positive two-year results from the Phase 2 open label extension study of donidalorsen in patients with hereditary angioedema streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Ionis Reports Positive Two-Year Results from Open-Label Phase 2 Extension Study of Donidalorsen in Patients With Hereditary Angioedema d1softballnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from d1softballnews.com Daily Mail and Mail on Sunday newspapers.